DIVISLAB2024-10-012024-12-31 DIVISLAB2024-10-012024-12-31 DIVISLAB2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member DIVISLAB2024-12-31 DIVISLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532488 DIVISLAB NOTLISTED Divi's Laboratories Limited Equity 2024-04-01 2025-03-31 2025-02-03 2025-01-23 INR Crores Third quarter 11:00:00 12:40:00 2025-02-03 2025-02-03 Not applicable Single segment Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients. 2024-10-01 2024-12-31 Unaudited Consolidated 23190000000.00 820000000.00 24010000000.00 10210000000.00 0.00 -990000000.00 2970000000.00 0.00 990000000.00 3570000000.00 16750000000.00 7260000000.00 0.00 7260000000.00 1740000000.00 -370000000.00 1370000000.00 0.00 5890000000.00 0.00 0.00 0.00 0.00 5890000000.00 10000000.00 5900000000.00 5890000000.00 0.00 5900000000.00 0.00 530000000.00 2 22.20 22.20 0.00 0.00 22.20 22.20 1. The above Statement of consolidated unaudited financial results for the quarter and nine months ended 31st December 2024 is prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Consolidated Statement is as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 3rd February 2025. The statutory auditors have carried out a limited review of the consolidated statement and issued an unmodified report thereon. 2.The consolidated unaudited financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”) 3.The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. 4.The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. 5.The Group has commenced commercial operations from a part of the Phase 1 of Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, India from January 01, 2025 6.During the quarter, the Holding Company has decided to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 from the current financial year. Accordingly, the current tax expenses and deferred tax expenses are estimated for the nine months ended 31st December 2024 and for the quarter ended on that date. 7.Forex gain included in Other Income for the respective periods is as given below. (Rs. in Crores) Quarter ended Nine Months ended Year ended 31.12.2024 30.09.2024 31.12.2023 31.12.2024 31.12.2023 31.03.2024 Forex gain 10 29 18 38 32 30 Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 67750000000.00 2660000000.00 70410000000.00 28900000000.00 0.00 -1460000000.00 8930000000.00 10000000.00 2950000000.00 10560000000.00 49890000000.00 20520000000.00 0.00 20520000000.00 5710000000.00 -480000000.00 5230000000.00 0.00 15290000000.00 0.00 0.00 0.00 0.00 15290000000.00 30000000.00 15320000000.00 15290000000.00 0.00 15320000000.00 0.00 530000000.00 2 57.60 57.60 0.00 0.00 57.60 57.60 Other Expenses 3570000000.00 Other Expenses 10560000000.00 Gain/(Loss) on Remeasurement of post-employment benefit obligations -10000000.00 Gain/(Loss) on Remeasurement of post-employment benefit obligations -20000000.00 -10000000.00 -20000000.00 -10000000.00 -10000000.00 Gain on exchange differences in translating the financial statements of foreign operations 10000000.00 Gain on exchange differences in translating the financial statements of foreign operations 50000000.00 10000000.00 50000000.00 0.00 10000000.00